Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-09-07

Clinical Trial Update: A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing LY2140023 with aripiprazole in schizophrenia was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ARIPIPRAZOLE (Aripiprazole)
  • LY2140023

Snippet

Sponsor: Denovo Biopharma LLC | Conditions: Schizophrenia | Phase 3 | Status: TERMINATED | Results posted: 2022-09-07